share_log

TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of Gavo-cel Phase 1/2 Trial; Showed 'Consistent Tumor Regression in 28 of 30 (93%) Evaluable Patients With Disease Control Rate of 77%'

Benzinga Real-time News ·  Sep 28, 2022 06:48

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit

- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel

- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%

- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma

- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes

- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET

CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment